Read our insights and commentary about industry news and innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 30 posts
May 3, 2019 | Videos
US Market Access Trends: CBPartners' Andrew Gould asks a panel of US payers which market access challenges are currently keeping them up at night.
May 1, 2019 | Blog
PART II of CBPartners' CNS series:
February 21, 2019 | Blog
Vermont’s fledgling drug importation law has undergone preliminary savings analysis, with uninspiring projections of a 3.8% drug cost savings rate. CBPartners evaluates the real impact of this new policy.
September 9, 2018 | Blog
When the engine of innovation gets the green light of marketing authorisation, it is typically first in the USA, and sometimes for the EMA’s (European Medicines Agency) jurisdiction over much of Europe. Unfortunately, China is too often one the last markets among the major and highest-tier of emerging markets to be considered for broad patient access. CBPartners explores the evolving reimbursement dynamics in China.
September 17, 2017 | Blog
Yet another drug pricing debate has started to brew in the USA, with its epicentre right in DC. Two Democratic members of the US House (Elijah Cummings (D-MD) and Peter Welch (D-VT)), announced that they are launching an investigation into the pricing of disease-modifying treatments for multiple sclerosis (MS). CBPartners investigates MS pricing in the political context.